3,107 reports of this reaction
2.6% of all ENZALUTAMIDE reports
#10 most reported adverse reaction
DIZZINESS is the #10 most commonly reported adverse reaction for ENZALUTAMIDE, manufactured by Astellas Pharma US, Inc.. There are 3,107 FDA adverse event reports linking ENZALUTAMIDE to DIZZINESS. This represents approximately 2.6% of all 117,902 adverse event reports for this drug.
Patients taking ENZALUTAMIDE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for ENZALUTAMIDE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for ENZALUTAMIDE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 3,107 FDA reports for ENZALUTAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.6% of all adverse event reports for ENZALUTAMIDE, making it a notable side effect.
If you experience dizziness while taking ENZALUTAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.